COMMUNIQUÉS West-GlobeNewswire

Nanobiotix Joins the Euronext Tech Leaders Index
02/06/2026
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
Bavarian Nordic Launches Next Tranche of Share Buy-Back Program
02/06/2026
COPENHAGEN, Denmark, June 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the third and final tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 [...]
FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
02/06/2026
Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the [...]
Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient
02/06/2026
Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient Well-established pharmaceutical technology business of Molecular [...]
Nanobiotix rejoint l'indice Euronext Tech Leaders
02/06/2026
PARIS et CAMBRIDGE, Mass., 02 juin 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
02/06/2026
Daix (France), New York City (New York, United States), le 2 juin 2026 – Inventiva (Euronext Paris et NASDAQ: IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une [...]
Santhera Announces Orphan Drug and Priority Review Designations for AGAMREE® (Vamorolone) in South Korea
02/06/2026
Pratteln, Switzerland, June 2, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that AGAMREE has been granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation by South [...]
Rapid Nutrition Expands Agentic AI Integration Across Consumer Wellness Ecosystem
02/06/2026
LONDON, June 02, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, is pleased to provide [...]
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
02/06/2026
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of [...]
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
02/06/2026
Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy 1 Giredestrant [...]
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
01/06/2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced [...]
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
01/06/2026
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock [...]
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
01/06/2026
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the [...]
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
01/06/2026
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
01/06/2026
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). SAN DIEGO, June 01, 2026 (GLOBE [...]
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06/2026
NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
01/06/2026
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Minerva [...]
Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère
01/06/2026
Abivax annonce des résultats majeurs de l’essai de maintenance de phase 3 ABTECT évaluant l’obéfazimod dans le traitement de la rectocolite hémorragique active modérée à sévère À la semaine 44, les deux doses d’ [...]
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
01/06/2026
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik ® (tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk profile of pociredir in [...]

Pages